Protocols · Longevity
FOXO4-DRI is a senolytic peptide designed to disrupt the FOXO4–p53 interaction and trigger apoptosis selectively in senescent cells. The evidence is a small number of mouse studies from the originating group, with limited independent replication and no human data.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
The intermittent 'hit and run' cycle structure is intrinsic to the senolytic hypothesis.
Selectivity for senescent over proliferating cells is the key measured property.
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
FOXO4-DRI · 10 mg Vial
FOXO4-DRI is dosed at 250 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg | 15 units (0.15 mL) |
A 5 mg vial in 1 mL gives 5 mg/mL. The D-amino-acid retro-inverso construction makes it costly to synthesise correctly, which makes identity verification unusually important.
Open the reconstitution calculatorThese are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
Baar MP, Brandt RMC, Putavet DA, et al. · Cell · 2017 · PMC5556182
Naturally aged and chemotherapy-aged mice were treated with intraperitoneal FOXO4-DRI peptide (daily or intermittent dosing, ~10 mg/kg range in the study protocols) to selectively induce apoptosis in senescent cells and restore fitness, fur density, and renal function.
View the recordHan X, Zhang T, Zhang Y, et al. · Journal of Cellular and Molecular Medicine · 2022 · DOI 10.1111/jcmm.17333
Mice with bleomycin-induced pulmonary fibrosis received intraperitoneal FOXO4-DRI peptide injections to selectively eliminate senescent myofibroblasts and reduce fibrosis.
View the recordPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.
